YouTube Facebook LinkedIn Google+ Twitter Xingrss  

Pricing Orphan Drugs


January 3, 2013 | NPS Pharmaceuticals is pricing Gattex, its drug for short bowel syndrome, at $295,000 per patient per year. How did they arrive at that number? Matthew Herper asks. Forbes
Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1


For reprints and/or copyright permission, please contact  Terry Manning, 781.972.1349 , tmanning@healthtech.com.